Linagliptina Pharmapath

Linagliptin, the active ingredient in Linagliptina Pharmapath, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH USA supplies Linagliptina Pharmapath as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycaemic control as monotherapy or in combination with other antidiabetic agents. Patients inadequately controlled on metformin: provides additional glucose‑lowering effect when added to metformin therapy. Patients with renal impairment: can be used without dose adjustment because it is eliminated primarily via the bile.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate headache. - Upper respiratory tract infection: symptoms of cold or flu. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including anaphylaxis, rash, or angioedema. - Hepatic injury: elevated liver enzymes or hepatitis. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Linagliptin should be used with clinical monitoring in the following situations: - Renal impairment: no dose adjustment needed but monitor renal function regularly. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Pregnancy: category C; discuss potential risks and benefits with the prescriber. - Elderly patients: monitor for hypoglycaemia, especially when combined with insulin or sulfonylureas. - Concomitant sulfonylureas: increased risk of hypoglycaemia; adjust dose if necessary. - Store at ambient temperature: keep below 25°C, protect from moisture and store in the original packaging.

Linagliptin may interact with several drug classes. Review the following interactions:

Major Interactions (Avoid): - Strong P‑glycoprotein inhibitors (e.g., itraconazole, ketoconazole): may increase linagliptin exposure. - Co‑administration with other DPP‑4 inhibitors: additive effect, not recommended.

Moderate Interactions (Monitor Closely): - Moderate P‑glycoprotein inhibitors (e.g., verapamil, amiodarone): may modestly raise plasma levels. - Insulin or sulfonylureas: increased risk of hypoglycaemia; dose adjustments may be required. - Drugs associated with pancreatitis (e.g., GLP‑1 analogues): monitor for pancreatic symptoms.